GLP-1 receptor agonists act to reduce insulin resistance by increasing glucose transporters, which in turn decreases inflammation, reduces oxidative stress, modulates lipid metabolism, promotes insulin secretion, slows gastric emptying, and inhibits macrophage secretion of inflammatory cytokines in insulin-dependent tissues. Here, INS is linked to Insulin resistance.